Loading…

Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia

The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-trans-retinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1986-01, Vol.4 (3), p.245-249
Main Authors: Peng, Y M, Alberts, D S, Graham, V, Surwit, E A, Weiner, S, Meyskens, Jr, F L
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283
cites cdi_FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283
container_end_page 249
container_issue 3
container_start_page 245
container_title Investigational new drugs
container_volume 4
creator Peng, Y M
Alberts, D S
Graham, V
Surwit, E A
Weiner, S
Meyskens, Jr, F L
description The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-trans-retinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 mu Ci) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.
doi_str_mv 10.1007/BF00179591
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77276379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77276379</sourcerecordid><originalsourceid>FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283</originalsourceid><addsrcrecordid>eNpFkU1LxDAQhoMoun5cvAs5eRCq-WrSHHVxVVjwoucym07XaLetSbqyf8NfbMVVTzO8PDww8xJyytklZ8xc3cwY48bmlu-QCc-NzJhWepdMGNcm09aaA3IY4ytjTFqj9sm-LHghhJ2QzymGtXfQ0ORjHJAOfYI3pF1NoWmyFKCNWcDk2847Cs5XtMLGrzFgRdceKFDXNQ0ssaWx79olZu7X6KD_hTfjMoZIfUt7SB7bFOmHTy_0j642sW8gejgmezU0EU-284g8z26fpvfZ_PHuYXo9z5zkRcqUqZXUMtfAkKvaKaNA5U4hF8ZIrEUuxyivtRGLCkEXQi6EQhTMWleIQh6R8x9vH7r3AWMqVz46HI9psRtiaYwwWho7ghc_oAtdjAHrsg9-BWFTclZ-F1D-FzDCZ1vrsFhh9YduPy6_AAJ9gig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77276379</pqid></control><display><type>article</type><title>Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia</title><source>Springer Nature - Connect here FIRST to enable access</source><creator>Peng, Y M ; Alberts, D S ; Graham, V ; Surwit, E A ; Weiner, S ; Meyskens, Jr, F L</creator><creatorcontrib>Peng, Y M ; Alberts, D S ; Graham, V ; Surwit, E A ; Weiner, S ; Meyskens, Jr, F L</creatorcontrib><description>The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-trans-retinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 mu Ci) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF00179591</identifier><identifier>PMID: 3818229</identifier><language>eng</language><publisher>United States</publisher><subject>Administration, Topical ; Cervix Uteri - metabolism ; Collagen ; Dose-Response Relationship, Drug ; Female ; Humans ; Tretinoin - administration &amp; dosage ; Tretinoin - metabolism ; Tritium ; Uterine Cervical Dysplasia - metabolism</subject><ispartof>Investigational new drugs, 1986-01, Vol.4 (3), p.245-249</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283</citedby><cites>FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3818229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Y M</creatorcontrib><creatorcontrib>Alberts, D S</creatorcontrib><creatorcontrib>Graham, V</creatorcontrib><creatorcontrib>Surwit, E A</creatorcontrib><creatorcontrib>Weiner, S</creatorcontrib><creatorcontrib>Meyskens, Jr, F L</creatorcontrib><title>Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-trans-retinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 mu Ci) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.</description><subject>Administration, Topical</subject><subject>Cervix Uteri - metabolism</subject><subject>Collagen</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Tretinoin - administration &amp; dosage</subject><subject>Tretinoin - metabolism</subject><subject>Tritium</subject><subject>Uterine Cervical Dysplasia - metabolism</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNpFkU1LxDAQhoMoun5cvAs5eRCq-WrSHHVxVVjwoucym07XaLetSbqyf8NfbMVVTzO8PDww8xJyytklZ8xc3cwY48bmlu-QCc-NzJhWepdMGNcm09aaA3IY4ytjTFqj9sm-LHghhJ2QzymGtXfQ0ORjHJAOfYI3pF1NoWmyFKCNWcDk2847Cs5XtMLGrzFgRdceKFDXNQ0ssaWx79olZu7X6KD_hTfjMoZIfUt7SB7bFOmHTy_0j642sW8gejgmezU0EU-284g8z26fpvfZ_PHuYXo9z5zkRcqUqZXUMtfAkKvaKaNA5U4hF8ZIrEUuxyivtRGLCkEXQi6EQhTMWleIQh6R8x9vH7r3AWMqVz46HI9psRtiaYwwWho7ghc_oAtdjAHrsg9-BWFTclZ-F1D-FzDCZ1vrsFhh9YduPy6_AAJ9gig</recordid><startdate>19860101</startdate><enddate>19860101</enddate><creator>Peng, Y M</creator><creator>Alberts, D S</creator><creator>Graham, V</creator><creator>Surwit, E A</creator><creator>Weiner, S</creator><creator>Meyskens, Jr, F L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19860101</creationdate><title>Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia</title><author>Peng, Y M ; Alberts, D S ; Graham, V ; Surwit, E A ; Weiner, S ; Meyskens, Jr, F L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Administration, Topical</topic><topic>Cervix Uteri - metabolism</topic><topic>Collagen</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Tretinoin - administration &amp; dosage</topic><topic>Tretinoin - metabolism</topic><topic>Tritium</topic><topic>Uterine Cervical Dysplasia - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Y M</creatorcontrib><creatorcontrib>Alberts, D S</creatorcontrib><creatorcontrib>Graham, V</creatorcontrib><creatorcontrib>Surwit, E A</creatorcontrib><creatorcontrib>Weiner, S</creatorcontrib><creatorcontrib>Meyskens, Jr, F L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Y M</au><au>Alberts, D S</au><au>Graham, V</au><au>Surwit, E A</au><au>Weiner, S</au><au>Meyskens, Jr, F L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1986-01-01</date><risdate>1986</risdate><volume>4</volume><issue>3</issue><spage>245</spage><epage>249</epage><pages>245-249</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><abstract>The present study was undertaken to evaluate the systemic absorption and cervical tissue uptake of all-trans-retinoic acid (TRA), delivered via a collagen spongecervical cap delivery device in patients with intraepithelial cervical dysplasia. Ten patients with histologically proven mild or moderate cervical dysplasia were included in this pharmacologic study. The two TRA concentrations (0.05% and 0.372%) selected for study represent the starting and maximally tolerated doses used in phase I clinical trial. All-trans-retinoic-11-3H acid (3H-TRA, 500 mu Ci) was used to facilitate cervical tissue uptake studies. Cervical biopsies and post-treatment blood samples were obtained from each patient after TRA exposure. The uptake of TRA into cervical tissues four hours after drug administration was significantly increased at the maximally tolerated TRA dose. There was a rapid decrease in cervical tissue concentration of TRA at the 0.372% dose between 4 and 24 h after drug exposure, suggesting a relatively short elimination half-life of TRA in cervical tissues. HPLC analysis of post-treatment blood samples indicate that there was no systemic absorption of TRA after local cervical administration.</abstract><cop>United States</cop><pmid>3818229</pmid><doi>10.1007/BF00179591</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0167-6997
ispartof Investigational new drugs, 1986-01, Vol.4 (3), p.245-249
issn 0167-6997
1573-0646
language eng
recordid cdi_proquest_miscellaneous_77276379
source Springer Nature - Connect here FIRST to enable access
subjects Administration, Topical
Cervix Uteri - metabolism
Collagen
Dose-Response Relationship, Drug
Female
Humans
Tretinoin - administration & dosage
Tretinoin - metabolism
Tritium
Uterine Cervical Dysplasia - metabolism
title Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dysplasia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A11%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cervical%20tissue%20uptake%20of%20all-trans-retinoic%20acid%20delivered%20via%20a%20collagen%20sponge-cervical%20cap%20delivery%20device%20in%20patients%20with%20cervical%20dysplasia&rft.jtitle=Investigational%20new%20drugs&rft.au=Peng,%20Y%20M&rft.date=1986-01-01&rft.volume=4&rft.issue=3&rft.spage=245&rft.epage=249&rft.pages=245-249&rft.issn=0167-6997&rft.eissn=1573-0646&rft_id=info:doi/10.1007/BF00179591&rft_dat=%3Cproquest_cross%3E77276379%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c318t-47f436356a0e14fc474a45c4e12773ef2534745f672bdea6823b24ee2099c8283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77276379&rft_id=info:pmid/3818229&rfr_iscdi=true